LifeMD (LFMD) Set to Announce Earnings on Thursday

LifeMD (NASDAQ:LFMD - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. LifeMD has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors that wish to register for the company's conference call can do so using this link.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to analyst estimates of $48.47 million. During the same quarter in the previous year, the company posted ($0.23) EPS. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Stock Performance

LifeMD stock remained flat at $4.15 during mid-day trading on Thursday. The company's stock had a trading volume of 258,439 shares, compared to its average volume of 735,099. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83. The stock has a market cap of $178.74 million, a P/E ratio of -5.93 and a beta of 1.18. The firm's 50-day moving average is $4.89 and its two-hundred day moving average is $6.81. LifeMD has a 1-year low of $3.99 and a 1-year high of $12.88.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LFMD. KeyCorp reduced their target price on LifeMD from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Thursday, July 11th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. Finally, B. Riley started coverage on LifeMD in a research note on Friday, August 23rd. They issued a "buy" rating and a $11.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.